BR0314713A - Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines. - Google Patents
Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.Info
- Publication number
- BR0314713A BR0314713A BR0314713-4A BR0314713A BR0314713A BR 0314713 A BR0314713 A BR 0314713A BR 0314713 A BR0314713 A BR 0314713A BR 0314713 A BR0314713 A BR 0314713A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- reagents
- diseases
- processes
- disorders associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
"PROCESSOS E REAGENTES PARA O TRATAMENTO DE DOENçAS E DISTúRBIOS ASSOCIADOS COM NìVEIS AUMENTADOS DE CITOCINAS PRó-INFLAMATóRIAS". A invenção refere-se a um processo para tratar um paciente diagnosticado com, ou em risco de desenvolver um distúrbio imunoinflamatório pela administração de um SSRI ou um análogo ou metabólito do mesmo e, opcionalmente, um corticosteróide ou outro composto ao paciente. A invenção também caracteriza uma composição farmacêutica contendo um SSRI ou análogo ou metabólito do mesmo e um costicoesteróide ou outro composto para o tratamento ou prevenção de um distúrbio imunoinflamatório."PROCESSES AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PRO-INFLAMMATORY CYTOKINES". The invention relates to a method of treating a patient diagnosed with or at risk of developing an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and optionally a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a costicosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41304002P | 2002-09-24 | 2002-09-24 | |
US41726102P | 2002-10-09 | 2002-10-09 | |
US42752602P | 2002-11-19 | 2002-11-19 | |
US42742402P | 2002-11-19 | 2002-11-19 | |
US46475303P | 2003-04-23 | 2003-04-23 | |
PCT/US2003/030156 WO2004030618A2 (en) | 2002-09-24 | 2003-09-24 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0314713A true BR0314713A (en) | 2005-07-26 |
Family
ID=32074779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0314713-4A BR0314713A (en) | 2002-09-24 | 2003-09-24 | Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1553955A4 (en) |
JP (1) | JP2006503905A (en) |
AR (1) | AR041386A1 (en) |
AU (1) | AU2003299196A1 (en) |
BR (1) | BR0314713A (en) |
CA (1) | CA2509526A1 (en) |
HR (1) | HRP20050355A2 (en) |
IS (1) | IS7811A (en) |
MX (1) | MXPA05003152A (en) |
NO (1) | NO20051669L (en) |
TW (1) | TW200422042A (en) |
WO (1) | WO2004030618A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200509958A (en) * | 2003-02-14 | 2005-03-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
WO2005030132A2 (en) * | 2003-09-24 | 2005-04-07 | Combinatorx, Incorporated | Therapeutic regimens for administering drug combinations |
CN1980649A (en) * | 2004-05-17 | 2007-06-13 | 康宾纳特克斯公司 | Methods and reagents for the treatment of immunoinflammatory disorders |
AU2011236053B2 (en) * | 2004-11-19 | 2014-06-26 | Merck Sharpe & Dohme B.V. | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
BRPI0517847A (en) * | 2004-11-19 | 2008-10-21 | Organon Nv | combination, uses of a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist, and method for the treatment of an individual of a vertebrate species suffering from depression or a related disorder. |
PL1719507T3 (en) * | 2005-04-13 | 2010-12-31 | Cipher Pharmaceuticals Inc | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin |
JP4832806B2 (en) * | 2005-06-03 | 2011-12-07 | 久光製薬株式会社 | Transdermal formulation |
TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
ATE531362T1 (en) * | 2006-09-08 | 2011-11-15 | Ore Pharmaceuticals Inc | METHOD FOR REDUCING OR RELIEVING INFLAMMATION IN THE DIGESTIVE TRACT |
US20080064709A1 (en) * | 2006-09-11 | 2008-03-13 | Duke University | Methods and compositions for the treatment of vascular depression |
GB0701171D0 (en) * | 2007-01-22 | 2007-02-28 | Imp Innovations Ltd | Compositions and uses thereof |
JP5740300B2 (en) * | 2009-02-27 | 2015-06-24 | 久光製薬株式会社 | Transdermal formulation |
PT117765A (en) * | 2022-01-28 | 2023-07-28 | Faculdade De Farmacia Da Univ De Lisboa | TOPICAL FORMULATION OF FLUVOXAMINE FOR THE TREATMENT OF PSORIASIS |
WO2024074699A1 (en) * | 2022-10-07 | 2024-04-11 | Oculis Operations Sarl | Eye drop microsuspensions of mtor inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993007863A1 (en) * | 1991-10-15 | 1993-04-29 | Mullarkey Michael F | Methods and compositions for treating allergic reactions |
GB9603137D0 (en) * | 1996-02-15 | 1996-04-17 | Merck Sharp & Dohme | Therapeutic agents |
WO1998002169A2 (en) * | 1996-07-15 | 1998-01-22 | Alza Corporation | Novel formulations for the administration of fluoxetine |
CA2282845A1 (en) * | 1997-03-18 | 1998-09-24 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6281248B1 (en) * | 2000-02-16 | 2001-08-28 | Magda Abdel Fattah Ahmed | Composition for treating asthma |
IL139975A0 (en) * | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
-
2003
- 2003-09-24 JP JP2005500317A patent/JP2006503905A/en active Pending
- 2003-09-24 BR BR0314713-4A patent/BR0314713A/en not_active IP Right Cessation
- 2003-09-24 AR ARP030103484A patent/AR041386A1/en unknown
- 2003-09-24 AU AU2003299196A patent/AU2003299196A1/en not_active Abandoned
- 2003-09-24 TW TW092126503A patent/TW200422042A/en unknown
- 2003-09-24 CA CA002509526A patent/CA2509526A1/en not_active Abandoned
- 2003-09-24 WO PCT/US2003/030156 patent/WO2004030618A2/en active Application Filing
- 2003-09-24 MX MXPA05003152A patent/MXPA05003152A/en not_active Application Discontinuation
- 2003-09-24 EP EP03756864A patent/EP1553955A4/en not_active Withdrawn
-
2005
- 2005-04-04 NO NO20051669A patent/NO20051669L/en not_active Application Discontinuation
- 2005-04-19 HR HR20050355A patent/HRP20050355A2/en not_active Application Discontinuation
- 2005-04-19 IS IS7811A patent/IS7811A/en unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20050355A2 (en) | 2005-10-31 |
CA2509526A1 (en) | 2004-04-15 |
WO2004030618A2 (en) | 2004-04-15 |
WO2004030618A3 (en) | 2005-04-07 |
JP2006503905A (en) | 2006-02-02 |
IS7811A (en) | 2005-04-19 |
TW200422042A (en) | 2004-11-01 |
AU2003299196A1 (en) | 2004-04-23 |
EP1553955A4 (en) | 2008-11-05 |
AR041386A1 (en) | 2005-05-18 |
EP1553955A2 (en) | 2005-07-20 |
MXPA05003152A (en) | 2006-04-27 |
NO20051669L (en) | 2005-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200509958A (en) | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | |
BRPI0415397A (en) | methods and reagents for the treatment of immunoinflammatory disorders | |
WO2005079284A3 (en) | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | |
BRPI0414435A (en) | methods and reagents for the treatment of immunoinflammatory disorders | |
BRPI0512220A (en) | method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound | |
BR0314713A (en) | Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines. | |
BRPI0512213A (en) | method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound | |
DE60331236D1 (en) | ORAL COMPOSITIONS FOR THE TREATMENT OF DIABETES | |
DE60216830D1 (en) | Pharmaceutical compositions for the treatment of disorders of the CNS or other diseases | |
ATE427129T1 (en) | DISPENSING DEVICE FOR MEDICINAL PRODUCTS | |
UA99094C2 (en) | Method for the treatment of patients with autoantibody positive disease | |
BR0213540A (en) | Compounds, method for treating a patient's illness or disorder and a pharmaceutical composition comprising them | |
WO2004043341A3 (en) | Treatment for hemorrhagic shock | |
BR0213100A (en) | Combinations for the treatment of immunoinflammatory disorders | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders | |
BRPI0411176A (en) | pharmaceutical combination consisting of modafinil and another drug | |
SG148186A1 (en) | Methods and reagents for the treatment of inflammatory disorders | |
BR0313413A (en) | Use of beta amyloid vaccination together with a selective cox-2 inhibitor for the treatment of alzheimer's disease | |
BR0310061A (en) | Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions | |
BRPI0416882A (en) | compound, pharmaceutical composition, method of treating a disorder, and use of a compound | |
UA89753C2 (en) | Use of a modafinil and an antidepressant for the treatment of depression and for decreasing the onset time of an antidepressant | |
BR9814867A (en) | Method for treating disease-related or drug-induced dyskinesias | |
BR0311180A (en) | Methods for treating respiratory diseases and conditions using a selective inhibitor of inos | |
DE60321954D1 (en) | SYNERGISTIC COMPOSITION CONTAINING ROFLUMILAST AND (R, R) -FORMOTEROL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: COMBINATORX, INCORPORATED (US) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060103181/RJ DE 11/07/2006. |
|
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 31/56; A61P 37/00 Ipc: A61K 31/56 (2011.01), A61P 37/00 (2011.01) |
|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |